Lv1
10 积分 2025-02-24 加入
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
20天前
已完结
Lead Optimization of Multimutant KRAS Switch-II Pocket Macrocyclic Inhibitors via Isosteric Replacement to Improve ADME and Oral Exposure
1个月前
已完结
Novel Highly Potent c-Met Degraders against a Broad Range of Cancers
1个月前
已完结
Olaparib-Cediranib Hybrid as Dual PARP-VEGFR3 Inhibitor Elicits Antitumor Efficacy: Rational Design, Synthesis, Biological Evaluation and Construction of a Charge Convertible pH Responsive Nanoformulation
2个月前
已完结
Brigatinib-associated autoimmune hepatitis: A case report
3个月前
已完结
Advancing targeted protein degradation for cancer therapy
4个月前
已完结
Driving Innovation: Ready, Set, Go!
4个月前
已完结
Bio-inspired self-assembled bacteriochlorin nanoparticles for superior visualization and photothermal ablation of tumors
6个月前
已完结
Analytical Methods in Pharmacoproteomics: A Systematic Review
8个月前
已关闭
皖公网安备34019202002308
